Key Details
Price
$1.36Annual EPS
-$4.24Annual ROE
987.83%Beta
0.80Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
July 22, 2021Recent annual earnings:
Mar 23, 2017Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 01, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today announced the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc. (‘IsoTherapeutics', a Telix Group company). This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics' lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda.
CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and clinically relevant longitudinal biomarkers AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), will present data demonstrating the utility of the CNSide CSF Assay Platform in identifying mutations of key biomarkers in the CSF and their implications in treatment selection for LM. The data will be presented at the 2024 Society for NeuroOncology (SNO) Annual Meeting November 21-24 in Houston, Texas.
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2024 Earnings Call Transcript November 14, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - VP and CFO Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.
AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx , a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a Manufacturing Services Agreement (MSA) for the production of Rhenium (186Re) Obisbemeda, an innovative radiotherapy for CNS cancers, including leptomeningeal metastases and recurrent glioblastoma. “In 2025, we intend to begin late-stage clinical trials and are actively preparing for commercial level product demand, therefore now is the time to expand our supply chain and partner with leading radiopharmaceutical manufacturers such as SpectronRx that can deliver for us and our patients,” said Marc H.
AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.
Plus Therapeutics, Inc. announced on May 8, 2024, that it awarded option grants to Charles Huang, the new Director of Capital Markets and Investor Relations.
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2023 Earnings Conference Call March 5, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Norman LaFrance - CMO Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen.
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Chief Medical Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen.
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will present data from its ReSPECT-LM clinical trial evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases at the Cancer Prevention & Research Institute of Texas (CPRIT) Innovations in Cancer Prevention and Research Conference VI. The conference is taking place October 2-3, 2023, in Galveston, Tex. The poster presentation is titled, Report of Phase 1 Part A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM) .
FAQ
- What is the primary business of Plus Therapeutics?
- What is the ticker symbol for Plus Therapeutics?
- Does Plus Therapeutics pay dividends?
- What sector is Plus Therapeutics in?
- What industry is Plus Therapeutics in?
- What country is Plus Therapeutics based in?
- When did Plus Therapeutics go public?
- Is Plus Therapeutics in the S&P 500?
- Is Plus Therapeutics in the NASDAQ 100?
- Is Plus Therapeutics in the Dow Jones?
- When was Plus Therapeutics's last earnings report?
- When does Plus Therapeutics report earnings?
- Should I buy Plus Therapeutics stock now?